Document is current
Any future updates will be listed below
-
Authors
Boussoffara, Thouraya
Labidi, Imen
Trimèche, Malek
Chelbi, Ifhem
Dachraoui, Khalil
Msallem, Nourhane
Abdo Saghir Abbas, Mohammed
Cherni, Saifedine
Singh, Kamaleshwar P.
Kaviraj, Swarnendu
Dey, Ranadhir https://orcid.org/0000-0003-0069-7867
Varikuti, Sanjay
Gannavaram, Sreenivas https://orcid.org/0000-0002-6557-8220
da S. Pereira, Lais
Zhang, Wen-Wei https://orcid.org/0000-0003-1996-876X
Lypaczewski, Patrick https://orcid.org/0000-0002-5550-712X
Hamano, Shinjiro https://orcid.org/0000-0003-3881-8337
Kato, Hirotomo
Singh, Sanjay
Louzir, Hechmi
Nakhasi, Hira L. https://orcid.org/0000-0003-4941-1620
Satoskar, Abhay R. https://orcid.org/0000-0001-5989-1520
Matlashewski, Greg https://orcid.org/0000-0002-8971-5525
Zhioua, Elyes
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 6 January 2025
First Online: 14 February 2025
Competing interests
: The FDA is currently the owner of two US patents that claim attenuated Leishmania species with the centrin gene deletion (US7,887,812 and US 8,877,213). All other authors declare no competing interests.
